Famotidine

Generic Name
Famotidine
Brand Names
Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
Drug Type
Small Molecule
Chemical Formula
C8H15N7O2S3
CAS Number
76824-35-6
Unique Ingredient Identifier
5QZO15J2Z8
Background

Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity to...

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.
...

Associated Conditions
Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions
Associated Therapies
-
Clinical Trials
Related News

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

First Posted Date
2021-05-26
Last Posted Date
2024-11-14
Lead Sponsor
Pfizer
Target Recruit Count
19
Registration Number
NCT04903093
Locations
🇺🇸

New Haven Clinical Research Unit, New Haven, Connecticut, United States

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

First Posted Date
2021-04-28
Last Posted Date
2024-08-09
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
129
Registration Number
NCT04862585
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma

First Posted Date
2021-04-12
Last Posted Date
2024-02-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2
Registration Number
NCT04840615
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

PROUD Study - Preventing Opioid Use Disorders

First Posted Date
2021-02-23
Last Posted Date
2023-06-22
Lead Sponsor
Emory University
Target Recruit Count
57
Registration Number
NCT04766996
Locations
🇺🇸

Emory University Orthopaedic and Spine Hospital, Atlanta, Georgia, United States

Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19

Phase 2
Active, not recruiting
Conditions
Covid-19
Interventions
Drug: Famotidine
Drug: Placebo
First Posted Date
2021-01-26
Last Posted Date
2022-04-12
Lead Sponsor
Northwell Health
Target Recruit Count
56
Registration Number
NCT04724720
Locations
🇺🇸

Northwell Health, Lake Success, New York, United States

An Outpatient Study Investigating Non-prescription Treatments for COVID-19

First Posted Date
2020-11-09
Last Posted Date
2022-09-30
Lead Sponsor
Profact, Inc.
Target Recruit Count
10
Registration Number
NCT04621149
Locations
🇺🇸

AZ Good Health Center, Tempe, Arizona, United States

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

First Posted Date
2020-11-04
Last Posted Date
2024-08-06
Lead Sponsor
Reema Padia
Target Recruit Count
65
Registration Number
NCT04614974
Locations
🇺🇸

UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19

Phase 1
Terminated
Conditions
Covid19
Interventions
Drug: Famotidine
Drug: N-Acetyl cysteine
First Posted Date
2020-09-10
Last Posted Date
2022-02-18
Lead Sponsor
Prisma Health-Upstate
Target Recruit Count
2
Registration Number
NCT04545008
Locations
🇺🇸

Prisma Health Greer Memorial Hospital, Greer, South Carolina, United States

🇺🇸

Prisma Health Baptist Easley Hospital, Easley, South Carolina, United States

🇺🇸

Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States

Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects

First Posted Date
2020-09-07
Last Posted Date
2021-03-09
Lead Sponsor
Calithera Biosciences, Inc
Target Recruit Count
22
Registration Number
NCT04540965
Locations
🇦🇺

Nucleus Network Brisbane Clinic (formerly Q-Pharm), Brisbane, Queensland, Australia

A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants

First Posted Date
2020-09-03
Last Posted Date
2021-10-06
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
56
Registration Number
NCT04536961
Locations
🇬🇧

Quotient Sciences Miami, Nottingham, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy